The NIH has funded foreign scientists since 1947. In 1960 the International Health Research Act formalised the practice. Its champion, John Fogarty, thought co-operation in medical research would foster peace. That is debatable, but the funding has done enormous good. The NIH’s Fogarty International Centre has trained thousands of health researchers in poorer countries; some alumni now run national health systems. Americans have benefited directly, too. For example, in 2021 an NIH-backed trial showed how to cure TB in four months rather than six. Trials are often faster and cheaper abroad. Enrolling patients is easier for conditions that are more common in other parts of the world, such as HIV. The Trump administration argues that overseas research can pose a national- security risk and that American taxpayers deserve better oversight. Those are reasonable concerns. The Wuhan Institute of Virology, one possible source of the covid-19 virus, received NIH money through its collaboration with the EcoHealth Alliance, a now-defunct American non-profit. Yet the administration’s approach to reform has been inept and indiscriminate, cutting off money for promising global research on arthritis, hiv, dementia and more. Our analysis suggests the administration’s political preoccupations have played a troubling role in the allocation of cash: research involving South Africa, with which Trumpworld has a beef about race politics, has suffered disproportionately. The damage to global science and America’s status at its summit is being aggravated by new immigration policies. Visa delays, travel bans and threats to post-study work rights have contributed to a fall of 21% in applications from international students to PhD programmes across 55 of America’s research universities. (New enrolments of other foreign students have also fallen dramatically.) In July a rule was finalised limiting student and exchange visas to four years, shorter than most PhD programmes, after which visa holders must apply for an extension (though this has since been blocked by a court). The Trump administration has proposed charging universities up to $100,000 per student for work authorisation for up to three years after graduation—a prohibitive sum. Deterring talented foreign scientists from coming to study and work in America is an act of senseless self-harm. Foreigners are not on the margins of science in America. A third of American Nobel laureates in the sciences
were born abroad. In 2023 roughly three-fifths of postdoctoral scientists held temporary visas. In Massachusetts, the de facto capital of America’s biotech industry, some 30% of STEM workers were born outside the country. America’s scientific engine would be far weaker without them. The Republican-controlled Congress has already pushed back against the White House, rejecting a proposed 40% cut to the NIH and refusing to abolish the Fogarty International Centre. The Democrats who will soon take over Congress should stiffen this defence and hold hearings to scrutinise the administration’s actions. So far, science does not feature much in their plans, raising the chances that its neglect will outlast Donald Trump’s presidency. Trust across international research networks takes years to build. So does a reputation for welcoming talented foreigners. There is no time to lose. ■ This article was downloaded by zlibrary from https://www.economist.com/leaders/2026/11/19/americas-neglect-of-global-science-is- backfiring
Bangladesh, an underappreciated success, faces an economic crisis A newish government must fix the country’s banks Nov 19th 2026 It would be seen as a giant, were it not bordered on three sides by India. With 180m people, Bangladesh is far more populous than any European country. And on November 24th its multitudes were supposed to achieve a new status. No longer was their country to be classed as “least-developed”, a UN category that allows poor nations cheap development loans and low- tariff access to rich markets. Bangladeshis were ready to celebrate. Sure, shirt- and skirt-exporters would lose an edge. But rising in this global league table would be a point of pride for a country that has much to be proud of. Bangladesh was born bloodily in 1971, when the former East Pakistan split from what was then called West Pakistan after a vile war. At the time, it was the second-poorest country in
the world. Since then it has quadrupled its income per head, slashed child mortality, educated nearly all of its children and become the world’s largest source of clothes after China. But the party was postponed. Although Bangladesh has earned promotion, it asked the UN for a three-year deferment, which was granted last month. Sadly, it needs the breathing space. After decades of progress it is suffering an economic crisis. Part of the blame lies with the thuggish regime of Sheikh Hasina Wajed, which was toppled in a student-led “Gen Z revolution” in 2024. It was replaced by an interim government and then, since February, by the Bangladesh Nationalist Party, the victor in an election from which Sheikh Hasina’s Awami League was barred. Before the revolution, Sheikh Hasina’s cronies looted Bangladesh’s banks, leaving them saddled with bad assets that add up to a third of the total loan book. Sheikh Hasina fled to India in 2024. But officials say her Awami League is behind strikes in the crucial garment industry and a campaign of crude bombs and arson. The League has reserves of ill-gotten cash and street fighters to draw on. If Sheikh Hasina comes back from exile, the chaos could intensify. Despite having been sentenced to death in absentia for her
part in a violent crackdown on protesters before she was toppled, she has vowed to return in December. Not all problems can be laid at Sheikh Hasina’s door. Some come from outside Bangladesh. Many factories were forced to close this year as the war in Iran disrupted fuel supplies from the Gulf. Costlier fuel spurred workers to demand higher wages, just as factory owners were least able to afford them; hence the strikes. The new government has been slow to grapple with inflation or corruption, and ham-fisted with protesters. Bangladesh risks an extended period of stagflation. Inflation has been over 8% since the middle of 2022, when it spiked following Russia’s invasion of Ukraine, which also put up energy prices. Growth in GDP is languishing around the levels seen during the covid-19 pandemic, at 3.5% in 2025, down from around 6%. Poverty is rising for the first time in decades, threatening to undo some of the country’s amazing progress. Inflation has outpaced wage growth for nearly five years. A shortage of good jobs, the original grievance of the student protesters, persists. A balance-of-payments crisis is unlikely. Payments to foreign creditors, though increasing, will remain small relative to foreign earnings from remittances and garment exports. The problem, rather, is a weakening domestic economy. Debt-service costs may reach 3% of GDP this year, straining public finances. Bangladesh collects only around 7% of GDP in tax. The most urgent priority is to fix Bangladesh’s banks. But if external creditors such as the IMF are to help the government bail them out, they are likely to want the government to rein in costly and distortive subsidies. That will be deeply unpopular. Bangladesh needs to use its three-year pause to push ahead with reforms that will help it stand on its own two feet. The government needs to boost its tax take. And it should be working hard to sign trade deals to replace preferential access, just as its neighbour India is. Escaping from extreme poverty and ousting a nasty regime is just the start. ■ This article was downloaded by zlibrary from https://www.economist.com/leaders/2026/11/19/bangladesh-an-underappreciated- success-faces-an-economic-crisis
Does private science hurt basic research? Also this week, inflation, longevity, defence secretaries, Poundbury, cats and dogs Nov 19th 2026 “Back to the bench” (October 24th) reported on America’s new era of private science. You noted the concerns about the present system of government-funded research, where the few committees that steer basic- research grants can lead to groupthink. I share that concern, but I also think that private control is no cure. In mining engineering, and I suspect elsewhere, university researchers increasingly compete with consulting firms for the money that industry supplies to tackle operational problems. But how many of those problems result from a failure to understand the mechanisms governing complex engineering systems, the very thing that basic research tackles? Some have also learned that controlling key conferences, and the papers they generate, is an effective launching pad for guidelines that persuade businesses to buy their services.
Dig deeper, as an academic is supposed to do, and this private work often cannot be reproduced because it rests on confidential documents. Ask to check their methods and results, and the reply is that the data are proprietary. Private science risks becoming closed to scrutiny and, consequently, an instrument for selling products and services rather than a means of discovery. Professor Davide ElmoNBK Institute of Mining EngineeringUniversity of British ColumbiaVancouver Your leader on science and AI saddened me, as its subtext seemed to suggest that science, much like commerce, is some kind of transactional exercise concerned only with an end point of making dull, useful things (“EurekAI!”, October 17th). Humans are reduced to safety inspectors overseeing the lot. Yet the great questions of science aren’t those that have already been asked just so that ever quicker large language models can dredge the dregs; they are about the magic of seeking the truth. It has been said that if a government committee had tried to cure polio we’d have ended up with super new iron lungs, not a vaccine. AI-driven science would be just as stupid. Looking up at the stars or peering inside a molecule and everywhere in between, wondering how these work, how they evolved: that is science. All the cool stuff that we end up with as a result is a secondary side-effect. To outsource science to AI would not be just a travesty but a tragedy. Dr Susan BaxterVancouver Tomas Philipson compared the change in the consumer-price level over the first 20 months of Donald Trump’s second administration with the change over the 48 months of Joe Biden’s time in office (By Invitation, November 7th). However, the increase in consumer prices during the Biden administration was front-loaded by developments it did not control. Compare that with a war of choice and tariff policies that the Trump government did control. Moreover, it is silly to think that American voters are looking for a decline in the average level of prices rather than their rate of change. Mr Philipson must know that a drop in the average level of prices (deflation) would be a disaster for the American economy at this point.